ClinVar Miner

Submissions for variant NM_001378454.1(ALMS1):c.11615_11616del (p.Ser3872fs)

dbSNP: rs1476205467
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Counsyl RCV000669201 SCV000793930 pathogenic Alstrom syndrome 2017-09-12 criteria provided, single submitter clinical testing
Invitae RCV000669201 SCV001215912 pathogenic Alstrom syndrome 2023-11-21 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Ser3873Tyrfs*19) in the ALMS1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ALMS1 are known to be pathogenic (PMID: 17594715). This variant is present in population databases (no rsID available, gnomAD 0.003%). This premature translational stop signal has been observed in individuals with ALMS1-related conditions (PMID: 26111748, 26969326, 29588463). ClinVar contains an entry for this variant (Variation ID: 553694). For these reasons, this variant has been classified as Pathogenic.
Blueprint Genetics RCV001075531 SCV001241157 pathogenic Retinal dystrophy 2018-12-04 criteria provided, single submitter clinical testing
Ambry Genetics RCV002369802 SCV002626138 pathogenic Cardiovascular phenotype 2021-08-23 criteria provided, single submitter clinical testing The c.11618_11619delCT pathogenic mutation, located in coding exon 17 of the ALMS1 gene, results from a deletion of two nucleotides at nucleotide positions 11618 to 11619, causing a translational frameshift with a predicted alternate stop codon (p.S3873Yfs*19). This mutation has been detected with other mutations in the ALMS1 gene in several individuals with Alstrom syndrome (Nadol JB et al. Audiol Neurootol, 2015 Jun;20:267-72; Citton V et al. J Neuroradiol, 2016 Jun;43:195-9; Sloan-Heggen CM et al. Hum Genet, 2016 Apr;135:441-450; Sanchez-Navarro I et al. Sci Rep, 2018 03;8:5285; Bea-Mascato B et al. Genes (Basel), 2021 02;12). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Natera, Inc. RCV000669201 SCV001455026 pathogenic Alstrom syndrome 2020-09-16 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.